{"entity":{"id":"ann-lii-cheng","kind":"person","name":"Ann-Lii Cheng","aka":[],"tldr":"Taiwanese oncologist who led the Asia-Pacific sorafenib trial and co-led IMbrave150, the immunotherapy standard for liver cancer.","summary":"Ann-Lii Cheng led the Asia-Pacific trial that confirmed sorafenib's benefit in hepatitis B-driven hepatocellular carcinoma and was co-principal investigator of IMbrave150, which established atezolizumab plus bevacizumab as first-line therapy. He has led or co-led most major HCC systemic therapy trials in Asia, including REFLECT (lenvatinib) and the adjuvant IMbrave050 study.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cheng%20AL%5BAuthor%5D%20hepatocellular"}],"tags":["hcc","immunotherapy","asia"],"related":[],"cancers":["hcc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pdl1","vegf"],"drugs":["atezolizumab"],"companies":[],"institutions":["ntuh"],"pathways":[],"terms":[],"trials":["imbrave150","reflect","imbrave050"],"people":[],"bottlenecks":[],"keyPapers":["paper-imbrave150-nejm-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Distinguished Professor and Director, National Taiwan University Cancer Center","institutionId":"ntuh","specialisms":["Hepatocellular carcinoma","Immunotherapy","Asia-Pacific trials","Targeted therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cheng%20AL%5BAuthor%5D%20hepatocellular"}],"papers":[{"title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","journal":"Lancet Oncology","year":2009,"doi":"10.1016/S1470-2045(08)70285-7"},{"title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","journal":"Journal of Hepatology","year":2022,"doi":"10.1016/j.jhep.2021.11.030"},{"title":"IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa1915745","doi":"10.1056/NEJMoa1915745"}],"orcid":"0000-0002-9152-6512"},"route":"/people/ann-lii-cheng/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"}],"institution":[{"id":"ntuh","kind":"institution","name":"National Taiwan University Hospital","route":"/institutions/ntuh/"}],"trial":[{"id":"imbrave050","kind":"trial","name":"IMbrave050","route":"/trials/imbrave050/"},{"id":"imbrave150","kind":"trial","name":"IMbrave150","route":"/trials/imbrave150/"},{"id":"reflect","kind":"trial","name":"REFLECT","route":"/trials/reflect/"}],"paper":[{"id":"paper-imbrave150-nejm-2020","kind":"paper","name":"IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer","route":"/key-papers/paper-imbrave150-nejm-2020/"}]}}